14-02-2013 дата публикации
Номер: US20130040831A1
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments. 1. A method of predicting whether a patient with diffuse large B-cell lymphoma (DLBCL) is likely to exhibit response to anti-CD20 therapy , comprising:(a) obtaining a sample from the patient;(b) determining in the sample the level of expression of one or more genes selected from U2AF1, RNF2, ZC3H7B, CCNI, PSMD11, ABLIM1, GYG2, CAMK2G, NF1, gene coding for cDNA clone EUROIMAGE 826033 (NCBI Accession No. BE858194), TRIM66, FBXO21, MKNK2, FYTTD1, GET4, CABLES2, FMNL3, C22orf27, TBCEL, ZNF707, the gene corresponding to NCBI Accession No. AI763196, CSTB, BAHCC1, LOC723809, NPIP, the gene coding for CDNA FLJ40566 fis (NCBI Accession No. AL576118), LOC730367, RXFP2, MGC24125, the gene coding for mRNA, differentially expressed in malignant melanoma, clone MM A2 (NCBI Accession No. AJ293390), PTP4A1, OSBP, HNRNPD, AHCYL1, BMP2K, IDS, SERPINB9, CSRP2BP, CD58, HERC4, MAGOH, TMBIM4, SFRS12, FAS, ZNF333, the gene corresponding to NCBI Accession No. AI127295, USP6, CHD6, LOC653160, the gene corresponding to NCBI Accession No. R64696, SRPR, MIR21, ARHGAP18, the gene corresponding to NCBI Accession No. AW004885, CBFA2T2, TIMP3, CTBS, USP16, RASA1 and YJEFN3;(c) determining whether the patient is likely to exhibit response to anti-CD20 therapy, based on the similarity between the level of expression of each gene measured in step (b) in the patient's sample and a set of control samples, where the expression of the corresponding genes has been determined.2. The method of claim 1 , wherein anti-CD20 therapy comprises an anti-CD20 antibody.3. The method of claim 1 , ...
Подробнее